基于临床化验指标重新计算的生物标记物在预测腹膜透析患者预后中的作用研究进展

Research advance in the role of predicting the prognosis of peritoneal dialysis patients by recalculated biomarkers based on clinical laboratory indicators

炎症及免疫、营养状态受损是腹膜透析患者预后不良的危险因素。由于炎症、免疫及营养之间关系错综复杂,复合生物标记物可能较单一生物标志物具有较佳的临床预后预测能力。近期研究表明,一些基于临床化验指标重新计算的生物标记物简单易得,可以较好反映身炎症、免疫及营养状态,对腹膜透析患者的结局有较好预测作用。本文综述了基于临床化验指标重新计算的生物标记物在预测腹膜透析患者预后中的作用研究进展,以期为临床腹膜透析患者的危险度分层与管理提供新思路。

Inflammation and impairment of immunity and nutrition are risk factors for poor prognosis in peritoneal dialysis patients. Due to the complex relationship among inflammation, immunity, and nutrition, composite biomarkers may have better clinical prognostic predictive ability than a single biomarker. Current research indicated that some biomarkers recalculated based on clinical laboratory indicators were simple and easy to obtain, which might have a better role in reflecting the status of inflammation, immunity, and nutrition, and in predicting the outcomes of peritoneal dialysis patients. This article reviewed the research progress on the role of biomarkers based on recalculated clinical laboratory indicators in predicting the prognosis of peritoneal dialysis patients, in order to provide new ideas for risk stratification and management of clinical peritoneal dialysis patients.